Rigel Pharmaceuticals, Inc.
RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warmā¦ read more
Healthcare
Biotechnology
25 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$41.59
Price-0.43%
-$0.18
1Y
Price
Market Cap
$742.221m
Small
Price/Earnings 3y Avg5y Avg
6.7x
Premium
Premium
Financials Overview
Key metrics over the past few years+43.4%
EBITDA Margin+40.2%
Net Profit Margin+34.6%
Free Cash Flow MarginRevenue
$282.076m
+57.3%
1y CAGR+36.0%
3y CAGR+22.1%
5y CAGREarnings
$113.300m
+548.0%
1y CAGR+258.3%
3y CAGR+137.0%
5y CAGREPS
$6.17
+523.2%
1y CAGR+249.9%
3y CAGR+135.1%
5y CAGRBook Value
$117.609m
$242.534m
Assets$124.925m
Liabilities$60.880m
DebtDebt to Assets
25.1%
0.5x
Debt to EBITDAFree Cash Flow
$68.140m
+119.3%
1y CAGR+147.1%
3y CAGR-268.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company